Printed From BioPortfolio.com

Intercept does not expect restrictive boxed warning for Ocaliva

12:19 EDT 25 Sep 2017 | Reuters

(Reuters) - Intercept Pharmaceuticals Inc said its liver drug, Ocaliva, could carry a boxed warning to help ensure proper dosing but does not expect the updated labeling to be restrictive, sending its shares higher.

Original Article: Intercept does not expect restrictive boxed warning for Ocaliva

Give dad the gift of knowledge. Order his DNA Ancestry kit this Father's Day for $99 at 23andMe! Ord

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

Biotech News by Location

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches

Topics

Intercept does not expect restrictive boxed warning for Ocaliva

More From BioPortfolio on "Intercept does not expect restrictive boxed warning for Ocaliva"

Relevant Topics

News Quicklinks